Brent Vaughan

CEO | Cognito Therapeutics

Brent Vaughan is Chief Executive Officer of Cognito Therapeutics. He has more than 20 years of experience as a serial founder and leader of teams developing proprietary technologies and innovative healthcare products across multiple domains, including pharmaceuticals, medical devices, and digital therapeutics. Prior to Cognito, Brent was Chief Executive Officer and Co-Founder at Cognoa, an AI-based digital therapeutics company, where he established the company as a leader in digital therapeutics and pediatric behavioral health. Under his leadership, Cognoa was awarded FDA Breakthrough Designation for the first two products for autism and successfully completed the clinical development of the lead product. He was also co-founder at WellnessFX, a leading digital health company. Brent has also held leadership positions in business development and product management in therapeutic and medical device companies including Saegis Pharmaceuticals, Nektar Therapeutics, and Roche. Brent is an avid skier, sailor, and enjoys spending time with his family and being outdoors

All Sessions by Brent Vaughan

  • October 18, 2023


  • 11:15 AM  - 11:55 AM
    Neuromodulation technologies have elicited strong expectations from investors. As products begin to close on commercial stages, companies are finding ways to work with physicians and patients to ensure these new tools can deliver. In this panel three executives from leaders in the space will share how they’re moving to build out the market for neuromodulation technologies.
    Bringing Devices to Market
    Where
    Room 210




Share

Brent Vaughan